Quarterly report pursuant to Section 13 or 15(d)

NOTE PAYABLE (Details Textual)

NOTE PAYABLE (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Sep. 28, 2016
Dec. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Sep. 30, 2013
Note Payable [Line Items]          
Interest Expense, Debt   $ 5,500 $ 2,800    
Debt instrument, unamortized discount   754,817   $ 977,882  
Note Payable [Line Items]          
Notes Payable   944,707      
2014 Warrant          
Note Payable [Line Items]          
Notes Payable   55,293      
Massachusetts Life Sciences Center          
Note Payable [Line Items]          
Subordinated Debt   $ 1,000,000     $ 1,000,000
Debt Instrument, Payment Terms (i) interest on the MLSC Loan decreased from 10% per annum to 7% per annum beginning October 3, 2016; and (ii) the MLSC Loan has now become due and payable on the earlier of October 3, 2017 (the Maturity Date), the occurrence of a Corporate Event (which is defined as the occurrence of either a Qualified Sale or Qualified Financing), or the occurrence of a Default (as defined in the promissory note issued in connection with the MLSC Loan Agreement). In addition, under the terms of the Amendment, (a) beginning October 3, 2016, the Company began amortizing the principal and accrued interest under the MLSC Loan by making the first of 13 monthly payments of approximately $106,022, with the last payment scheduled to occur on the Maturity Date; and (b) the term Qualified Financing is now defined to mean one or more financing transactions in which we receive, in a single transaction or series of transactions, cumulative net proceeds of not less than five million dollars ($5,000,000) at any time after October 3, 2016. The loan originally bore interest at a rate of 10% per annum, and was originally scheduled to become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction (a Qualified Sale) or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period (a Qualified Financing)      
Warrants Issued To Purchase Of Common Stock         145,985
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 0.27
Debt Instrument, Increase, Accrued Interest $ 232,000        
Debt Instrument, Interest Rate, Stated Percentage 7.00%